MONARCC: a randomised phase II study of panitumumab monotherapy and panitumumab plus 5-fluorouracil as first-line therapy for RAS and BRAF wildtype metastatic colorectal cancer: a study by the Australasian Gastrointestinal Trials Group (AGITG).

doi:10.1186/s12885-021-08644-4

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

MONARCC: a randomised phase II study of panitumumab monotherapy and panitumumab plus 5-fluorouracil as first-line therapy for RAS and BRAF wildtype metastatic colorectal cancer: a study by the Australasian Gastrointestinal Trials Group (AGITG).

BMC cancer - 18 Aug 2021

Siu Ho Wai Derrick, Tebbutt Niall, Chantrill Lorraine, Karapetis Chris, Steer Christopher, Wilson Kate, Espinoza David, Bailey Lisa, Yip Sonia, Cuff Jeff, Pavlakis Nick, Thavaneswaran Subotheni, Briscoe Karen, Srivastav Ratnesh, Shannon Jennifer, Segelov Eva, Tie Jeannie, Caird Susan, Francesconi Alessandra, Price Timothy, Wuttke Melanie, Ladwa Rahul, Sjoquist Katrin, Burge Matthew

Abstract excerpt

BACKGROUND: Doublet chemotherapy in combination with a biologic agent has been a standard of care in patients with metastatic colorectal cancer for over a decade. The evidence for a "lighter" treatment approach is limited to mono-chemotherapy plus bevacizumab in the RAS unselected population. Anti-EGFR antibodies have activity as monotherapy or in combination with chemotherapy in RAS wildtype metastatic...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Combined Chemotherapy Protocols

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Clinical Trials, Phase II as Topic

Share to Fluorouracil

Share to Multicenter Studies as Topic

Share to Neoplasm Metastasis

Share to Panitumumab

Share to Randomized Controlled Trials as Topic

Share to ras Proteins

Source

Open in PubMed Open full text

Identifiers

PMID: 34407800
DOI: 10.1186/s12885-021-08644-4
PMCID: PMC8371602

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

MONARCC: a randomised phase II study of panitumumab monotherapy and panitumumab plus 5-fluorouracil as first-line therapy for RAS and BRAF wildtype metastatic colorectal cancer: a study by the Australasian Gastrointestinal Trials Group (AGITG).PMID 34407800Read ↗

The PANDA study: a randomized phase II study of first-line FOLFOX plus panitumumab versus 5FU plus panitumumab in RAS and BRAF wild-type elderly metastatic colorectal cancer patients.Semantic proximity Read ↗

Sotorasib plus panitumumab and 5-fluorouracil in first-line treatment of patients with unresectable KRAS G12C mutated colorectal cancer unfit for a doublet/triplet chemotherapy: ENGIC 01 - PRODIGE 107 - FFCD 2306 - COLOSOTO trial.Semantic proximity Read ↗

FOLFIRI plus panitumumab in the treatment of wild-type KRAS and wild-type NRAS metastatic colorectal cancer.Semantic proximity Read ↗

Evidence-Based Second-Line Treatment in RAS Wild-Type/Mutated Metastatic Colorectal Cancer in the Precision Medicine Era.Semantic proximity Read ↗

Panitumumab safety for treating colorectal cancer.Semantic proximity Read ↗

Update on optimal treatment for metastatic colorectal cancer from the ACTG/AGITG expert meeting: ECCO 2015.Semantic proximity Read ↗

Evidence-based appraisal of the upfront treatment for unresectable metastatic colorectal cancer patients.Semantic proximity Read ↗

First-Line Treatment of Metastatic Colorectal Cancer: Interpreting FIRE-3, PEAK, and CALGB/SWOG 80405.Semantic proximity Read ↗

Systematic review of randomised clinical trials and observational studies for patients with RAS wild-type or BRAFV600E-mutant metastatic and/or unresectable colorectal cancer.Semantic proximity Read ↗

Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer.Semantic proximity Read ↗

Treatment of extended RAS/BRAF wild-type metastatic colorectal cancer with anti-EGFR antibody combinations.Semantic proximity Read ↗

Combination therapy of bevacizumab with either S-1 and irinotecan or mFOLFOX6/CapeOX as first-line treatment of metastatic colorectal cancer (TRICOLORE): Exploratory analysis of RAS status and primary tumour location in a randomised, open-label, phase III, non-inferiority trial.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.